OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Kidney Journal is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Prolonged normothermic perfusion: a promising approach to kidney transplantation	213
A puzzling renal Fanconi syndrome	107
Donor-derived membranous nephropathy	91
Correction to: Recognition of intraglomerular histological features with deep learning in protocol transplant biopsies and their association with kidney function and prognosis	67
Circulating miR-129-3p in combination with clinical factors predicts vascular calcification in hemodialysis patients	67
Toward acid- and heparin-free dialysis: the regional anticoagulation approach	67
Can exercise improve outcomes for frail haemodialysis patients?	61
Risk factors for acute kidney injury and kidney relapse in patients with lupus podocytopathy	56
Complement activation in anti-glomerular basement membrane disease before and after treatment with imlifidase	56
Probability of chronic kidney disease and associated risk factors in Chinese adults: a cross-sectional study of 9 million Chinese adults in the Meinian Onehealth screening survey	56
But how green is it actually? Calculating the environmental footprint of kidney care environmental optimizations within haemodialysis	55
Risk factors for steroid-induced osteonecrosis of the femoral head in children with immune kidney disease	55
The “Leicester, Leicestershire, and RUtland Chronic Kidney Disease Integrated Care Delivery Project” (LUCID) programme update: the impact on novel kidney therapies	54
Novel eGFR equations and cardiovascular outcomes in a multiethnic Asian cohort	50
Bilateral nephrectomy in autosomal dominant polycystic kidney disease patients before or after renal transplantation: data from a retrospective cohort study	49
Cerebral blood flow following successful living kidney transplantation: the VINTAGE study	46
Standardization of serum creatinine is essential for accurate use of unbiased estimated GFR equations: evidence from three cohorts matched on renal function	46
Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic	44
Alleviating symptoms in patients undergoing long-term hemodialysis: a focus on chronic kidney disease-associated pruritus	43
Non-invasive assessment of IgA nephropathy severity with [18F]AlF-NOTA-FAPI-04 PET/CT imaging	43
Use of eHealth and remote patient monitoring: a tool to support home dialysis patients, with an emphasis on peritoneal dialysis	43
Galectin-3 as a prognostic biomarker in haemodialysis patients with preserved or mildly reduced ejection fraction	42
The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations	42
Making use of avacopan in clinical practice	41
Microvascular perfusion, perfused boundary region and glycocalyx shedding in patients with autosomal dominant polycystic kidney disease: results from the GlycoScore III study	40

Recent advances in pathogenetic concepts and disease modeling of IgA nephropathy	40
Plant-based diets for CKD patients: fascinating, trendy, but feasible? A green nephrology perspective	40
10 tips on performing economic evaluation in kidney disease	39
Interaction of general obesity and abdominal obesity with frailty in patients with chronic kidney disease: a nationally representative analysis	39
Association between frailty and bone health in early-stage chronic kidney disease: a study from the population-based CARTaGENE cohort	38
Erythroferrone is associated with the hepcidin-to-ferritin ratio and cardiovascular mortality in chronic kidney disease	38
Meet and greet but avoid the heat: a reflection on the carbon footprint of congresses prompted by ERA2023	37
Biomarkers in clinical epidemiology studies	37
Causal relationships between immune cell phenotypes and primary glomerular diseases: genetic evidence from bidirectional Mendelian randomization study	37
Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study	36
Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case–control study	36